NXC-201 CAR-T therapy advances toward first approval for AL amyloidosis
New CapabilitiesImmix Biopharma's single-dose cell therapy posts deep remissions in a registrational Phase 2 trial
May 21st, 2026: Interim Phase 2 readout: 95% complete responseNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated May 21Immix Biopharma reported Thursday that 19 of 20 patients in its NEXICART-2 Phase 2 trial reached complete remission with NXC-201, a one-time CAR-T cell therapy for AL amyloidosis. The 95% complete response rate is up from 75% in an earlier readout, and all four patients with minimal-residual-disease-negative status have now converted to complete responses.
AL amyloidosis kills patients by depositing toxic protein in the heart, kidneys, and nerves. Those who relapse after standard chemotherapy have a median survival under a year, and no CAR-T therapy is currently approved for the disease. Immix is enrolling 45 patients in the registrational trial and plans to file for FDA approval after the full readout.
Why it matters
If cleared, NXC-201 would be the first one-time cell therapy for AL amyloidosis, a disease that often kills relapsed patients within a year.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Keyboard: ↓/L lower · ↑/H higher
0 points — sign up to put that on the leaderboard.
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Sign up to keep a daily streak — a new puzzle lands every day.
Exit debate?
Your progress in this debate will be lost.
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
Select debater for this side:
No debate personas available right now.
Select debater for this side:
No debate personas available right now.
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Round Results
Set the Crossfire
Pick the question both personas must answer in the final round
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Prediction History
People Involved
Organizations Involved
California-based clinical-stage company developing NXC-201, an autologous BCMA-directed CAR-T therapy.
Jerusalem teaching hospital where NXC-201 was invented and first dosed in patients.
The U.S. agency that clears drugs and biologics for sale.
Timeline
2017 May 2026
-
Interim Phase 2 readout: 95% complete response
Latest ClinicalImmix reports 19 of 20 patients in deep remission, up from 75% earlier; no relapses to date. Topline data expected Q3 2026.
-
FDA grants RMAT designation
RegulatoryRegenerative Medicine Advanced Therapy status opens a faster review path and more FDA contact.
-
Trial moves to expansion cohort
ClinicalNEXICART-2 advances into its expansion cohort after early dosing meets safety bars.
-
FDA clears NEXICART-2 trial
RegulatoryInvestigational New Drug application clears, allowing the US multi-center Phase 1b/2 study to start.
-
FDA grants orphan drug designation
RegulatoryNXC-201 receives orphan status for AL amyloidosis and multiple myeloma, qualifying for tax credits and exclusivity.
-
Immix in-licenses NXC-201 from Hadassah
DealCalifornia-based Immix Biopharma pays Hadassah about $20 million plus future milestones for global rights.
-
First patients dosed in Jerusalem
ClinicalHadassah's single-center NEXICART-1 trial treats the first multiple myeloma and AL amyloidosis patients with NXC-201.
-
Hadassah starts work on academic CAR-T
ResearchPolina Stepensky and Cyril Cohen begin developing the BCMA-targeted CAR-T that becomes NXC-201.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
Kymriah becomes the first FDA-approved CAR-T (2017)
The FDA approved Novartis's tisagenlecleucel (Kymriah) for children and young adults with relapsed B-cell acute lymphoblastic leukemia. Pivotal trial data showed an 83% remission rate in a population with few options. The agency cleared it three months ahead of its decision date.
Kymriah launched at $475,000 per infusion and forced insurers, hospitals, and Medicare to build new payment and delivery systems for one-time cell therapies.
Eight more CAR-T therapies have since been approved, building the regulatory and manufacturing template Immix is following with NXC-201.
Kymriah set the precedent for high-priced, one-time cell therapies in blood cancers with no other good options. AL amyloidosis would be the next major category if NXC-201 clears.
Abecma approved as first BCMA CAR-T for multiple myeloma (2021)
The FDA approved Bristol Myers Squibb and bluebird bio's idecabtagene vicleucel (Abecma) for adults with relapsed or refractory multiple myeloma after four prior therapies. The pivotal KarMMa trial showed a 72% response rate and 28% complete response rate. It was the first BCMA-targeted cell therapy of any kind to reach market.
Abecma and the follow-on Carvykti generated more than $1 billion in combined annual sales by 2024 and shifted myeloma treatment toward earlier cell therapy use.
BCMA CAR-Ts have set the safety expectations the FDA now applies to NXC-201, which targets the same antigen in a different plasma cell disease.
AL amyloidosis is driven by the same plasma cells that cause multiple myeloma. Abecma proved BCMA CAR-T can work clinically and commercially. NXC-201 is the closest analog in a sibling disease.
Darzalex Faspro becomes first drug specifically approved for AL amyloidosis (2021)
The FDA approved Janssen's subcutaneous daratumumab plus chemotherapy for newly diagnosed AL amyloidosis based on the ANDROMEDA trial, which showed a 53% complete hematologic response rate compared with 18% on chemotherapy alone. It was the first therapy ever approved with an AL amyloidosis label.
Daratumumab quickly became the front-line standard of care and roughly doubled deep response rates in newly diagnosed patients.
It established AL amyloidosis as a commercially viable indication, encouraging programs like NXC-201 to target patients who relapse after daratumumab-based regimens.
Darzalex defines the standard of care that NXC-201 patients have failed before enrolling. The 95% complete response rate in NEXICART-2 is roughly double what daratumumab produced in newly diagnosed disease, and these are sicker patients.
